Search clinical trials for: 4b - rMenB OMV NZ and routine vaccines

Total 123 results

Novartis Vaccines

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Meningococcal Disease

Austria, Finland, Germany, Italy, Czech Republic
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
GlaxoSmithKline

Not yet recruiting

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Meningitis, Meningococcal

Korea, Republic of
University Hospitals Bristol and Weston NHS Foundation...
Public Health England; University of Bristol; Novartis Vaccines; North Bristol...

Completed

Regulation of Mucosal Immune Response to Systemic MenB Vaccine

Meningococcal Infections

United Kingdom
GlaxoSmithKline

Completed

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Meningitis, Meningococcal

Czechia
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
Novartis Vaccines
GlaxoSmithKline

Completed

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Prevention of the Meningococcal Disease

Germany
GlaxoSmithKline

Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Infections, Meningococcal

Chile, Canada, Australia
Novartis Vaccines

Completed

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

Meningococcal Disease | Meningococcal Meningitis

Chile
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Meningococcal Disease

Chile
Novartis

Completed

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Meningitis, Meningococcal, Serogroup B

Poland
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Infections, Meningococcal

Mexico, Argentina
GlaxoSmithKline

Completed

A Sourcing Study to Collect Human Blood Samples From Healthy Adults

Meningitis, Meningococcal

Australia, Germany
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Novartis Vaccines

Completed

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Meningococcal Disease | Meningococcal Meningitis

Spain, Brazil, Hungary, Peru
Novartis Vaccines

Completed

Novartis Vaccine and Diagnostics Carriage Trial

N. Meningitidis Carriage

United Kingdom
Novartis Vaccines

Completed

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Healthy

United Kingdom
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

Meningococcal Infections

Belgium, Czech Republic, Germany, Italy, Spain, United Kingdom
GlaxoSmithKline

Active, not recruiting

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Infections, Meningococcal

United States, Italy
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Meningococcal Disease

Korea, Republic of
Novartis Vaccines

Completed

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Meningococcal Disease | Meningococcal Meningitis

Spain, Italy, United Kingdom, Czech Republic
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
GlaxoSmithKline

Completed

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

Infections, Meningococcal

United States, Australia, Finland, Estonia, Canada, Turkey, Czechia
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Meningococcal Disease

Italy, Poland, Russian Federation, Spain, United Kingdom
GlaxoSmithKline

Active, not recruiting

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Infections, Meningococcal

United States, Puerto Rico
Novartis Vaccines
Novartis

Completed

A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults

Meningococcal Disease | Meningococcal Meningitis

Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus

Cytomegalovirus Infection | Healthy, no Evidence of Disease

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Meningococcal Disease

United States
Public Health England

Completed

Meningococcal B Vaccination in University Students (MNB3)

Neisseria Meningitidis Serogroup B

United Kingdom
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal

United States, Australia, Argentina, Canada
Serum Institute of India Pvt. Ltd.
Centers for Disease Control and Prevention; University of Colorado, Boulder

Completed

A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices (PMV-001)

Prophylaxis for the Measles Infection

India
City of Hope Medical Center
National Cancer Institute (NCI); Diavax Biosciences

Active, not recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Lymphadenopathy | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated Phase... and other conditions

United States
City of Hope Medical Center

Withdrawn

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Hematopoietic Cell Transplantation Recipient | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated... and other conditions

United States
GlaxoSmithKline

Completed

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Meningococcal Disease | Infections, Meningococcal

Colombia, Panama, Chile
Children's Hospital Medical Center, Cincinnati
Centers for Disease Control and Prevention

Completed

Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study

Intussusception | Rotavirus Infections

United States
CMV Research Foundation
International AIDS Vaccine Initiative

Completed

Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age

Cytomegalovirus

United States
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Infections

Philippines
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

Nonneoplastic Condition

United States
Daniel Landi
Pediatric Brain Tumor Foundation; Annias Immunotherapeutics, Inc.

Active, not recruiting

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)

Malignant Glioma | Recurrent Medulloblastoma | Recurrent Brain Tumor, Childhood

United States
Themis Bioscience GmbH
Walter Reed Army Institute of Research (WRAIR)

Completed

Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area

Chikungunya

Puerto Rico
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors

Cytomegalovirus Infections

United States
Merck Sharp & Dohme LLC

Completed

Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)

Gastroenteritis | Rotavirus Infections
Virginia Commonwealth University
CMV Research Foundation Inc

Terminated

Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women

Cytomegalovirus Infections

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Infections, Meningococcal

Finland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
Pfizer

Terminated

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Meningitis, Meningococcal

Spain
University of California, San Francisco
Vical

Completed

Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge

Cytomegalovirus Infection

United States

3

Subscribe